Hangzhou Diagens Biotechnology (2526) Stock Overview
A medical devices company, develops medical imaging products and services. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
2526 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hangzhou Diagens Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$307.20 |
| 52 Week High | HK$428.00 |
| 52 Week Low | HK$178.00 |
| Beta | 0 |
| 1 Month Change | -13.46% |
| 3 Month Change | 55.15% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 46.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2526 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 1.5% | -6.1% | -4.7% |
| 1Y | n/a | -17.6% | -4.2% |
Return vs Industry: Insufficient data to determine how 2526 performed against the Hong Kong Medical Equipment industry.
Return vs Market: Insufficient data to determine how 2526 performed against the Hong Kong Market.
Price Volatility
| 2526 volatility | |
|---|---|
| 2526 Average Weekly Movement | 14.0% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2526's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2526's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 166 | Ning Song | www.diagens.com |
Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company’s products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image acquisition, and output of chromosome or cell samples for a range of cytogenetics applications, including genetics health, radiation health, and hemato-oncology; and KayoFlow automatic cell harvester for pre-analytical processing of various sample types, including peripheral blood, amniotic fluid, and bone marrow.
Hangzhou Diagens Biotechnology Co., Ltd. Fundamentals Summary
| 2526 fundamental statistics | |
|---|---|
| Market cap | HK$27.30b |
| Earnings (TTM) | -HK$77.47m |
| Revenue (TTM) | HK$189.74m |
Is 2526 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2526 income statement (TTM) | |
|---|---|
| Revenue | CN¥164.42m |
| Cost of Revenue | CN¥46.34m |
| Gross Profit | CN¥118.09m |
| Other Expenses | CN¥185.22m |
| Earnings | -CN¥67.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 71.82% |
| Net Profit Margin | -40.83% |
| Debt/Equity Ratio | 0% |
How did 2526 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 16:27 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hangzhou Diagens Biotechnology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.